Orphan drug designation for uveitis treatment approved

Article

Santen announced the FDA approval of the orphan drug designation of sirolimus, a uveitis treatment.

Santen announced the FDA approval of the orphan drug designation of sirolimus, a uveitis treatment.

The FDA approval follows the European Commission's decision to grant sirolimus orphan drug status in September 2011. Sirolimus, otherwise known as rapamycin, is used as an immunosuppressive and antiproliferative agent for the treatment of chronic/refractory anterior non-infectious uveitis, intermediate uveitis, panuveitis and uveitis affecting the posterior segment of the eye.

Currently, sirolimus is being assessed in the Phase III study SAKURA (Study Assessing Double-Masked Uveitis Treatment). The investigation will be used to determine the safety and efficacy of various sirolimus doses used to treat non-infectious posterior uveitis.

Dr Toshiaki Nishihata, Head of Research and Development Division, said, "This is an important milestone in the development of sirolimus for non-infectious uveitis affecting the posterior segment of the eye."

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.